Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Discovery Labs Inc (DSCO) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 31,620
  • Shares Outstanding, K 8,150
  • Annual Sales, $ 990 K
  • Annual Income, $ -55,170 K
  • 36-Month Beta 1.65
  • Price/Sales 17.70
  • Price/Book 3.81
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -6.30
  • Most Recent Earnings N/A on N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.43 +144.76%
on 03/29/16
3.93 -10.94%
on 04/15/16
+1.85 (+112.12%)
since 03/18/16
3-Month
1.42 +146.48%
on 01/26/16
3.93 -10.94%
on 04/15/16
+0.84 (+31.58%)
since 01/15/16
52-Week
1.42 +146.48%
on 01/26/16
18.34 -80.92%
on 04/22/15
-12.18 (-77.68%)
since 04/17/15

Most Recent Stories

More News
Discovery Labs Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Discovery Laboratories, Inc. (NASDAQ: DSCO), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that its Board of Directors has...

Discovery Labs Announces Appointment of New Chief Executive Officer and Provides an Update on AEROSURF® Phase 2 Program

Discovery Laboratories, Inc. (NASDAQ: DSCO), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced the appointment of a new Chief...

Discovery Labs Announces Reverse Stock Split

Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that it has filed a Certificate of Amendment ("Amendment") to its Amended and Restated Certificate of Incorporation, as previously amended ("Certificate...

Discovery Laboratories Advances Respiratory Disease Drug

Discovery Laboratories, Inc. (DSCO) announced that it has initiated a phase IIb study.

Discovery Laboratories Advances Respiratory Disease Drug

Discovery Laboratories, Inc. (DSCO) announced that it has initiated a phase IIb study.

Discovery Labs Announces Initiation of AEROSURF® Phase 2b Clinical Trial

Discovery Laboratories, Inc. (NASDAQ: DSCO), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has initiated its AEROSURF®...

Results of AEROSURF® Phase 2a Clinical Program in Premature Infants 29 to 34 Weeks Gestational Age Presented at the 2015 Hot Topics in Neonatology Annual Meeting

Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that data from the AEROSURF® Phase 2a clinical program in premature infants 29 to 34 weeks gestational age (GA) with respiratory distress syndrome...

Discovery Labs to Announce Results from AEROSURF® Phase 2a Expansion Clinical Trial

Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will announce top-line results from its...

Discovery Labs Provides Business Update and Reports Third Quarter 2015 Financial Results

Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today provided a business update and...

Discovery Labs Announces Completion of Enrollment in AEROSURF® Phase 2a Dose Expansion Trial

Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has completed...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Discovery Laboratories, Inc., formerly known as Ansan Pharmaceuticals, Inc., is a development-stage pharmaceutical company that focuses on developing compounds to treat respiratory diseases that affect the ability of the lungs to absorb oxygen. It is initially developing its lead product candidate, Surfaxin,...

See More

Support & Resistance

2nd Resistance Point 3.98
1st Resistance Point 3.74
Last Price 3.50
1st Support Level 3.38
2nd Support Level 3.26

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.